Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alimera Sciences Inc's ILUVIEN Receives Marketing Authorization In Spain For Treatment Of Chronic Diabetic Macular Edema


Thursday, 17 Jan 2013 07:30am EST 

Alimera Sciences Inc announced that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. 

Company Quote

6.25
0.14 +2.29%
12:56pm EDT